Those who accepted the deal received new shares of preferred stock in exchange for existing preferred stock, according to a Theranos announcement. Founder and CEO Elizabeth Holmes gave shares and equity to offset the effect of those who chose not to participate in the deal.
The deal comes after news in April that Ms. Holmes was $25 million in debt to the company after buying stock and deferring payment.
The transaction was intended to bring investors together “around forward-looking business plans,” according to the announcement. The company is now shifting focus from its finger-prick blood testing device to a product called the miniLab, which runs tests on larger sample sizes of blood.
More articles on leadership and management:
AMA calls on Senate to maintain ACA’s insurance gains: 3 things to know
5 traits of a high-performance culture — and 8 steps to start building one today
OSU Wexner Medical Center faculty still distressed after CEO’s resignation